86 articles
A 21,000-person imaging study reveals visceral fat, liver fat, and muscle fat infiltration accelerate cardiovascular ageing differently by sex.
A Cochrane review of 37 RCTs finds obesity drugs modestly reduce weight in adolescents, but evidence quality is low and long-term data are absent.
A new study links GLP-1 agonists to dramatic survival benefits in breast cancer patients, but experts warn the results are likely too good to be true.
Three major longevity industry shifts converge: open AI datasets, GLP-1 longevity drugs, and a systems-level rethink of aging science.
New NPF primer finds GLP-1 receptor agonists improve psoriasis outcomes and quality of life when added to standard treatments in obese patients.
Dive into the molecular machinery behind lifelong brain health — from BDNF-TrkB signaling cascades and adult hippocampal neurogenesis to glymphatic amyloid clearance and cutting-edge interventions including senolytics, GLP-1 agonists, and transcranial stimulation.
New research confirms obesity causally worsens psoriasis, and GLP-1 agonists plus diet changes may improve both skin and systemic health.
Mayo Clinic review covers every FDA-approved obesity medication plus pipeline drugs, with head-to-head weight loss data and clinical best practices.
Antag Therapeutics reports AT7687 is well tolerated in humans and drives weight loss in primates when combined with cagrilintide.
Dr. Uri Alon uses a simple village model to reframe aging as a balance between damage accumulation and cleanup capacity.
Major review sparks fresh controversy over effectiveness of amyloid-targeting Alzheimer's treatments currently approved by FDA.
Review explores how GLP-1 receptor agonists revolutionize type 2 diabetes care through improved blood sugar control and significant weight reduction.
